TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3166107

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (300 mg) taken orally once a week
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 29554400

Group type: EXPERIMENTAL
Intervention: Anterior palatoplasty
Number of subjects: 45

Group type: COMPARATOR
Intervention: Uvulopalatal flap procedure
Number of subjects: 45
Study: 29354955

Group type: EXPERIMENTAL
Intervention: Reinforcing‐reducing manipulation with 'guoyanre' manipulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reinforcing‐reducing method
Number of subjects: 68
Study: 25775675

Group type: EXPERIMENTAL
Intervention: Nitinol stent placement
Number of subjects: 246

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study: 23993259

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times daily
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Celebrex 200 mg daily
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study: 20584708

Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ringer
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 18271901

Group type: EXPERIMENTAL
Intervention: Serum lithium levels of 0.6-0.75 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum lithium levels >0.75 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrupt reduction of serum lithium levels >0.2 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum lithium level of 0.4 mmol/L
Number of subjects: 0
Study: 16049976

Group type: EXPERIMENTAL
Intervention: Clinical Examination of the Breast (CBE) carried out by trained nurses, with 5 annual screenings planned.
Number of subjects: 151168

Group type: EXPERIMENTAL
Intervention: CBE intervention
Number of subjects: 151168
Study: 14624369

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) plus nevirapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 nucleoside reverse‐transcriptase inhibitors (NRTIs) plus nevirapine
Number of subjects: 0
Study: 10355238

Group type: EXPERIMENTAL
Intervention: Lists of words that were associates of a common word (critical target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: List generated from 'king'
Number of subjects: 0
Study: 9097716

Group type: EXPERIMENTAL
Intervention: Mineral and cholesterol depositions in the tissues of patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy with energy dispersive x‐ray analyses (microprobe‐SEM/EDXA) and atomic absorption spectroscopy (AAS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Localized cations imbalance
Number of subjects: 10
Study: 2085103

Group type: EXPERIMENTAL
Intervention: Human milk protein (HMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adapted cow's milk protein (CMP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both HMP and CMP
Number of subjects: 20
Study: 391628

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 100
Study: 31126775

Group type: EXPERIMENTAL
Intervention: Patellar Resurfacing (PR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-Patellar Resurfacing (non-PR)
Number of subjects: 84
Study: 27512098

Group type: EXPERIMENTAL
Intervention: Tui Na therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo Tui Na therapy
Number of subjects: 90
Study: 25561389

Group type: EXPERIMENTAL
Intervention: Group 2 (multimedia information including a movie on third molar extraction)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Group 1 (basic information given verbally)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group (basic information given verbally without operative procedures and recovery information)
Number of subjects: 333
Study: 24955104

Group type: EXPERIMENTAL
Intervention: Diaoshi Jifa treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 21840846

Group type: EXPERIMENTAL
Intervention: Low spatial frequency (SF) gratings (magnocellularly biased)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF) gratings (parvocellularly biased)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 0
Study: 19465233

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg per day
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 17251982

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg b.i.d. for 6.5 days with rifampin 600 mg once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan 125 mg b.i.d. for 6.5 days
Number of subjects: 0
Study: 16050851

Group type: EXPERIMENTAL
Intervention: CKTnI testing
Number of subjects: 392

Group type: COMPARATOR
Intervention: CK testing alone
Number of subjects: 392
Study: 11967516

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg capsule per day for 6 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 66
Study: 9480948

Group type: EXPERIMENTAL
Intervention: CHO/Pro/fat (66% CHO, 23% Pro, 11% fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHO (1 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 10
Study: 7659630

Group type: EXPERIMENTAL
Intervention: Comprehensive care project aimed at improving information and communication
Number of subjects: 177

Group type: COMPARATOR
Intervention: Pre-project evaluation
Number of subjects: 177
Study: 3233720

Group type: EXPERIMENTAL
Intervention: Electrical tooth stimulation at varying intensities
Number of subjects: 8
Study: 30305049

Group type: EXPERIMENTAL
Intervention: $50 prepaid incentive check
Number of subjects: 0

Group type: COMPARATOR
Intervention: $50 promised (postpaid) incentive check
Number of subjects: 0
Study: 28664840

Group type: EXPERIMENTAL
Intervention: 4% or 15% citrate anticoagulation
Number of subjects: 140
Study: 25532460

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 192
Study: 23549037

Group type: EXPERIMENTAL
Intervention: Treatment with cisplatin
Number of subjects: 433

Group type: COMPARATOR
Intervention: Treatment without cisplatin
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: BRCA1 positive patients
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: XRCC1 Gln/Gln genotype
Number of subjects: 433
Study: 20511564

Group type: EXPERIMENTAL
Intervention: Calcium-phosphate cement (Ca-PO(4)) used for indirect pulp-capping with acid conditioning prior to application.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium-phosphate cement (Ca-PO(4)) used for indirect pulp-capping without acid conditioning.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated group (control).
Number of subjects: 0
Study: 18179482

Group type: EXPERIMENTAL
Intervention: Home visiting program (8 visits, 1 hour each, over 18 months) by experienced home nurses with telephone follow-up.
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 330
Study: 20233343

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16298751

Group type: EXPERIMENTAL
Intervention: Daily fruit (blueberries) consumption (250 g) for three weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acute fruit ingestion (250 g)
Number of subjects: 20
Study: 11573659

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those who did not respond to commands)
Number of subjects: 40
Study: 9692416

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 82
Study: 7888847

Group type: EXPERIMENTAL
Intervention: Ventricular ectopy of more than 100 beats during the day
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Ventricular ectopy of more than 100 beats at night
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Multifocal ventricular ectopic beats during the day
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Multifocal ventricular ectopic beats at night
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Sinoatrial pauses exceeding 1.5 seconds during the day
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Sinoatrial pauses exceeding 1.5 seconds
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Night time multifocal ventricular ectopy
Number of subjects: 480

Group type: COMPARATOR
Intervention: Findings on ambulatory electrocardiography
Number of subjects: 480
Study: 3109146

Group type: EXPERIMENTAL
Intervention: 5 g Mezlocillin administered at the time of narcosis for 20 min followed by 0.5 g Metronidazol for 10 min, given in 8-hour intervals for three days post-surgery.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Mezlocillin and Metronidazol) administered 30 min preoperatively and continued for three days postoperatively.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotic treatment).
Number of subjects: 50
Study: 30545653

Group type: EXPERIMENTAL
Intervention: Closed incisional negative pressure wound therapy (ciNPWT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Silver-impregnated occlusive dressing (control)
Number of subjects: 160
Study: 30221851

Group type: EXPERIMENTAL
Intervention: Access to personalized video recordings of patient-physician counseling
Number of subjects: 101

Group type: COMPARATOR
Intervention: No access to personalized video recordings
Number of subjects: 101
Study: 26507336

Group type: EXPERIMENTAL
Intervention: Group A (Inofolic® plus): myo-inositol 4000 mg, folic acid 400 mcg, melatonin 3 mg
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Group B (Inofolic®): myo-inositol 4000 mg, folic acid 400 mcg
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group: only folic acid 400 mcg
Number of subjects: 526
Study: 25102786

Group type: EXPERIMENTAL
Intervention: Core curriculum in urology clerkships
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Web-based resources during clerkship
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Urology interest group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mandatory urology clinical clerkship
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Elective urology clerkship
Number of subjects: 41

Group type: COMPARATOR
Intervention: No urology lectures or coursework
Number of subjects: 41
Study: 24278989

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19328351

Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: External dacryocystorhinostomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-operated sides (control)
Number of subjects: 44
Study: 17724259

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 14716729

Group type: COMPARATOR
Intervention: Active prevention agents or placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-oxidants
Number of subjects: 0
Study: 11881102

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 9683207

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (stavudine and nelfinavir)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Prolonged induction therapy (saquinavir and nelfinavir)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Induction therapy (stavudine, lamivudine, saquinavir, and nelfinavir)
Number of subjects: 62
Study: 7830804

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg i.m. once a week for 12 weeks, followed by tapering oral dose
Number of subjects: 15
Study: 3146726

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin (16 mg/kg per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-dose cyclosporin (9 mg/kg per day) with azathioprine (1 mg/kg per day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin followed by conversion to azathioprine
Number of subjects: 80
Study: 29265187

Group type: EXPERIMENTAL
Intervention: Drinking apple juice (0 ml, 50 ml, 100 ml, 200 ml, 300 ml, 400 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cut-off value of 9.6 cm2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Linear predictive model based on antral cross-sectional area
Number of subjects: 60
Study: 26840338

Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals (24±3 hours)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Fixed dosing intervals (24 hours)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals
Number of subjects: 198

Group type: COMPARATOR
Intervention: Fixed dosing intervals
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Flexible and Fixed dosing intervals
Number of subjects: 198
Study: 25070545

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed-dose)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 488
Study: 23658438

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Etidronate (400 mg daily)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination therapy (Atorvastatin + Etidronate)
Number of subjects: 108
Study: 20669576

Group type: EXPERIMENTAL
Intervention: AO locked compressive plates (LCP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Humeral head replacement
Number of subjects: 58
Study: 18387406

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral formulation
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study: 16608514

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (25 g soy protein containing 60 mg isoflavones)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control protein devoid of isoflavones
Number of subjects: 87
Study: 12420194

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10599151

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone replacement therapy
Number of subjects: 6
Study: 7499737

Group type: EXPERIMENTAL
Intervention: 500 micrograms sulprostone in 250 saline solution infused at a rate of 100 micrograms/h 12 hours before the abortion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol per os 3 hours before abortion
Number of subjects: 90

Group type: COMPARATOR
Intervention: 400 micrograms misoprostol per os 12 hours before abortion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sulprostone
Number of subjects: 90

Group type: COMPARATOR
Intervention: misoprostol
Number of subjects: 90
Study: 1723196

Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 17
Study: 6258106

Group type: EXPERIMENTAL
Intervention: gamma-acetylenic GABA (GAG)
Number of subjects: 14
Study: 30922760

Group type: EXPERIMENTAL
Intervention: Moderate-pain walking
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pain-free walking
Number of subjects: 36
Study: 28703478

Group type: EXPERIMENTAL
Intervention: Biomaterial 1 (B1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BoneCeramic (BC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Biomaterial 2 (B2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clot (C)
Number of subjects: 48
Study: 25813773

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 35
Study: 24200700

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 5 mg with sufentanil 2.5 μg followed by epidural 2% lidocaine 5 mL (Group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 10 mg with sufentanil 2.5 μg followed by epidural saline 5 mL (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group L
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 40
Study: 20939022

Group type: EXPERIMENTAL
Intervention: Screening measure comprised of 13 items rated on a 4-point scale, reviewed by two program faculty members.
Number of subjects: 0
Study: 19016830

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 268

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 268
Study: 17556865

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 59
Study: 15446522

Group type: EXPERIMENTAL
Intervention: ACL-PCL
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: MLP
Number of subjects: 344

Group type: COMPARATOR
Intervention: PS
Number of subjects: 344

Group type: COMPARATOR
Intervention: PCL
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: ACL-PCL and MLP
Number of subjects: 344
Study: 11422013

Group type: EXPERIMENTAL
Intervention: oral ARTS (150 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: oral DHA (120 mg)
Number of subjects: 25
Study: 10447842

Group type: EXPERIMENTAL
Intervention: Standardized patients with a tutor to student ratio of 1.5:10
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group with traditional inpatient encounters and a tutor to student ratio of 3:10
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 8549572

Group type: EXPERIMENTAL
Intervention: Sucrose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose polymer solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (330 ml)
Number of subjects: 6
Study: 2356344

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (15 ml)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (20 ml)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (25 ml)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bupivacaine 0.75% (15 ml)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (15 ml)
Number of subjects: 77
Study: 116537

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 12
Study: 31092139

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study: 30172900

Group type: EXPERIMENTAL
Intervention: Lettuce seed (1000 mg daily for two weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26898299

Group type: EXPERIMENTAL
Intervention: Amatuximab
Number of subjects: 0
Study: 23839031

Group type: EXPERIMENTAL
Intervention: Dual adaptation with visual cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual adaptation with postural cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single adaptation
Number of subjects: 0
Study: 22257013

Group type: EXPERIMENTAL
Intervention: MF101
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 20356440

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (treatment group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 33
Study: 18793398

Group type: EXPERIMENTAL
Intervention: Behavior therapy for depression prior to standard weight loss treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard weight loss treatment alone
Number of subjects: 174
Study: 16354802

Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.5 mg kg(‐1) day(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.75 mg kg(‐1) day(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.0 mg kg(‐1) day(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.5 mg kg(‐1) day(‐1)
Number of subjects: 120
Study: 14668277

Group type: EXPERIMENTAL
Intervention: 30 mg lysine/kg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 45 mg lysine/kg/d
Number of subjects: 14
Study: 10375057

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet (protein 12% of total energy)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (protein 25% of total energy)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 65
Study: 8728664

Group type: EXPERIMENTAL
Intervention: Soft splint
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hard splint
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unsplinted control
Number of subjects: 39
Study: 1521727

Group type: EXPERIMENTAL
Intervention: Simvastatin (10-20 mg/day) for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment (baseline vs 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment (baseline vs 12 weeks)
Number of subjects: 26
Study: 6651612

Group type: EXPERIMENTAL
Intervention: Colestipol (30 grams/day), Niacin (7.3 grams/day), and diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 14
Study: 4027129

Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study: 30916916

Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) and motor imagery (MI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional rehabilitation (mime-therapy and myofascial-approach)
Number of subjects: 22